Caicun Zhou

14PUBLICATIONS
67CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Dec 01, 2025
Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.

Jian Fang, Ou Jiang, Wei Li

|Nov 14, 2025
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Fei Zhou, Yuan Li, Jian Ming

|Jun 27, 2025
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Caicun Zhou, Rose Huang, Yuan Yuan

|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.

Caicun Zhou, Xiaorong Dong, Gongyan Chen

|Nov 03, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.

Wei Li, Yongsheng Wang, Anwen Xiong

|Jan 05, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Caicun Zhou, Ziping Wang, Meili Sun

Pageof 3

Frequent Collaborators

3 joint publications

Fei Zhou

2 joint publications

Ying Cheng

2 joint publications

Yongqian Shu

2 joint publications

Fengying Wu